BRD4 and hepatocellular carcinoma: Given the heterogeneous nature of HCC, we first evaluated the expression of both CHEK1 and BRD4 when HCC patient samples were stratified into three molecular subtypes, iCluster1‐3, by integrating multiomics analyses as described previously.56